免疫检查点抑制剂相关性胆管炎诊治研究进展

doi:10.3969/j.issn.1672-5069.2025.01.039

摘要/Abstract

摘要： 目的免疫检查点抑制剂的应用越来越广泛,在治疗肿瘤患者方面占据重要地位,随之而来的不良反应也不可忽视,其中胆管损伤发病较为罕见,但后者一旦发生,对免疫抑制治疗不敏感,而需要个体化治疗。本文介绍了免疫检查点抑制剂相关性胆管损伤的流行病学、发病机制、生化指标、临床表现、病理学和影像学表现及治疗管理方面的研究进展,为临床处理提供参考。

关键词: 免疫检查点抑制剂, 胆管炎, 胆管损伤, 临床特征

Abstract: The application of immune checkpoint inhibitors is becoming more and more extensive,which plays an important role in the treatment of patients with malignant neoplasmas,and the adverse events are more common.Bile duct injury is rare, but once happening, the immunosuppressive therapy tends to be insensitive in most patients,so individualized management is recommended. In this article, we review the epidemiology,pathogenesis,biochemical indexes,clinical and pathological manifestations,imaging and treatment of patients with immune checkpoint inhibitors-associated bile duct injury.

Key words: Immune checkpoint inhibitors-associated cholangitis, Bile duct injury, Clinical feature

王益杰, 李成忠. 免疫检查点抑制剂相关性胆管炎诊治研究进展[J]. 实用肝脏病杂志, 2025, 28(1): 152-155.

Wang Yijie, Li Chengzhong. Immune checkpoint inhibitor-related cholangitis:current states of the art[J]. Journal of Practical Hepatology, 2025, 28(1): 152-155.

参考文献

[1] Martins F,Sofiya L,Sykiotis GP,et al.Adverse effects of immune-checkpoint inhibitors:epidemiology,management and surveillance.Nat Rev Clin Oncol,2019,16(9):563-580.
[2] Postow MA,Callahan MK,Wolchok JD.Immune checkpoint blockade in cancer therapy.J Clin Oncol,2015,33(17):1974-1982.
[3] Borghaei H,Paz-Ares L,Horn L,et al.Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer.N Engl J Med,2015,373(17):1627-1639.
[4] Gauci ML,Lanoy E,Champiat S,et al.Long-term survival in patients responding to anti-PD-1/PD-L1 therapy and disease outcome upon treatment discontinuation.Clin Cancer Res,2019,25(3):946-956.
[5] Postow MA,Sidlow R,Hellmann MD.Immune-related adverse events associated with immune checkpoint blockade.N Engl J Med,2018,378(2):158-168.
[6] Regev A,Avigan MI,Kiazand A,et al.Best practices for detection,assessment and management of suspected immune-mediated liver injury caused by immune checkpoint inhibitors during drug development.J Autoimmun,2020,114:102514.
[7] Hoofnagle JH,Björnsson ES.Drug-induced liver injury-types and phenotypes.N Engl J Med,2019,381(3):264-273.
[8] Gelsomino F,Vitale G,D’Errico A,et al.Nivolumab-induced cholangitic liver disease:a novel form of serious liver injury.Ann Oncol,2017,28(3):671-672.
[9] Kawakami H,Tanizaki J,Tanaka K,et al.Imaging and clinicopathological features of nivolumab-related cholangitis in patients with non-small cell lung cancer.Invest New Drugs,2017,35(4):529-536.
[10] Hountondji L,Ferreira De Matos C,Lebossé F,et al.Clinical pattern of checkpoint inhibitor-induced liver injury in a multicentre cohort.JHEP Rep,2023,5(6):100719.
[11] Kashima J,Okuma Y,Shimizuguchi R,et al. Bile duct obstruction in a patient treated with nivolumab as second-line chemotherapy for advanced non-small-celllung cancer:a case report.Cancer Immunol Immunother,2018,67(1):61-65.
[12] Mizuno K,Ito T,Ishigami M,et al.Real world data of liver injury induced by immune checkpoint inhibitors in Japanese patients with advanced malignancies.J Gastroenterol,2020,55(6):653-661.
[13] Takinami M,Ono A,Kawabata T,et al.Comparison of clinical features between immune-related sclerosing cholangitis and hepatitis.Invest New Drugs,2021,39(6):1716-1723.
[14] Cheung V,Gupta T,Payne M,et al.Immunotherapy-related hepatitis:real-world experience from a tertiary centre.Frontline Gastroenterol,2019,10(4):364-371.
[15] Cohen JV,Dougan M,Zubiri L,et al.Immune checkpoint inhibitor related liver injury:Histopathologic pattern does not correlate with response to immune suppression.Mod Pathol,2021,34(2):426-437.
[16] Pi B,Wang J,Tong Y,et al.Immune-related cholangitis induced by immune checkpoint inhibitors:a systematic review of clinical features and management.Eur J Gastroenterol Hepatol,2021,33(Suppl 1):e858-e867.
[17] Shojaie L,Ali M,Iorga A,et al.Mechanisms of immune checkpoint inhibitor-mediated liver injury.Acta Pharm Sin B,2021,11(12):3727-3739.
[18] Rudd CE,Taylor A,Schneider H.CD28 and CTLA-4 coreceptor expression and signal transduction.Immunol Rev,2009,229(1):12-26.
[19] Qureshi OS,Zheng Y,Nakamura K,et al.Trans-endocytosis of CD80 and CD86:a molecular basis for the cell-extrinsic function of CTLA-4.Science,2011,332(6029):600-603.
[20] Boussiotis VA.Molecularand biochemical aspects of the PD-1 checkpoint pathway.N Engl J Med,2016,375(18):1767-1778.
[21] Buchbinder EI,Desai A.CTLA-4 and PD-1 pathways:similarities,differences,and implications of their inhibition.Am J Clin Oncol,2016;39(1):98-106.
[22] Keir ME,Butte MJ,Freeman GJ,et al.PD-1 and its ligands in tolerance and immunity.Annu Rev Immunol,2008,26:677-704.
[23] Doherty GJ,Duckworth AM,Davies SE,et al.Severe steroid-resistant anti-PD1 T-cell checkpoint inhibitor-induced hepatotoxicity driven by biliary injury.ESMO Open,2017,2(4):e000268.
[24] Stein S,Henze L,Poch T,et al.IL-17A/F enable cholangiocytes to restrict T cell-driven experimental cholangitis by upregulating PD-L1 expression.J Hepatol,2021,74(4):919-930.
[25] Onoyama T,Takeda Y,Yamashita T,et al.Programmed cell death-1 inhibitor-related sclerosing cholangitis:A systematic review.World J Gastroenterol,2020,26(3):353-365.
[26] Yamamoto T,Mizuno K,Ito T,et al.Abdominal pain accompanied by elevated serum inflammatory markers and biliary enzymes for diagnosing immune checkpoint inhibitor-induced sclerosing cholangitis.Invest New Drugs,2023,41(3):512-521.
[27] Nakano R,Shiomi H,Fujiwara A,et al.Clinical characteristics of ICI-related pancreatitis and cholangitis including radiographic and endoscopic findings.Healthcare (Basel),2022,10(5):763.
[28] Sawada K,Shonaka T,Nishikawa Y,et al.Successful treatment of nivolumab-related cholangitis with prednisolone: a case report and review of the literature.Intern Med,2019,58(12):1747-1752.
[29] Zen Y,Chen YY,Jeng YM,et al.Immune-related adverse reactions in the hepatobiliary system: second-generation check-point inhibitors highlight diverse histological changes.Histopathology,2020,76(3):470-480.
[30] Zen Y,Yeh MM.Hepatotoxicity of immune checkpoint inhibitors:a histology study of seven cases in comparison with autoimmune hepatitis and idiosyncratic drug-induced liver injury.Mod Pathol,2018,31(6):965-973.
[31] Gelsomino F,Vitale G,Ardizzoni A.A case of nivolumab-related cholangitis and literature review:how to look for the right tools for a correct diagnosis of this rare immune-related adverse event.Invest New Drugs,2018,36(1):144-146.
[32] Moi L,Bouchaab H,Mederos N,et al.Personalized cytokine-directed therapy with tocilizumab for refractory immune checkpoint inhibitor-related cholangiohepatitis.J Thorac Oncol,2021,16(2):318-326.
[33] Nabeshima S,Yamasaki M,Matsumoto N,et al.Atezolizumab-induced sclerosing cholangitis in a patient with lung cancer:a case report.Cancer Treat Res Commun,2021,26:100270.
[34] Bonkovsky HL,Kleiner DE,Gu J,et al.Clinical presentations and outcomes of bile duct loss caused by drugs and herbal and dietary supplements.Hepatology,2017,65(4):1267-1277.
[35] Nakanuma Y,Tsuneyama K,Harada K.Pathology and pathogenesis of intrahepatic bile duct loss.J Hepatobiliary Pancreat Surg,2001,8(4):303-315.
[36] Anderson MA,Kurra V,Bradley W,et al.Abdominal immune-related adverse events: detection on ultrasonography,CT,MRI and ¹⁸F-Fluorodeoxyglucose positron emission tomography.Br J Radiol,2021,94(1118):20200663.
[37] Mekki A,Dercle L,Lichtenstein P,et al.Detection of immune-related adverse events by medical imaging in patients treated with anti-programmed cell death 1.Eur J Cancer,2018,96:91-104.
[38] Chu D,Adler DG.Malignant biliary tract obstruction: evaluation and therapy.J Natl Compr Canc Netw,2010,8(9):1033-1044.
[39] Katabathina VS,Dasyam AK,Dasyam N,et al.Adult bile duct strictures:role of MR imaging and MR cholangiopancreatography in characterization.Radiographics,2014,34(3):565-586.
[40] Brahmer JR,Lacchetti C,Thompson JA.Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy:American society of clinical oncology clinical practice guideline summary. J Oncol Pract,2018,14(4):247-249.
[41] Thompson JA,Schneider BJ,Brahmer J,et al.Management of immunotherapy-related toxicities,version 1.2019.J Natl Compr Canc Netw,2019,17(3):255-289.
[42] Arbour KC,Mezquita L,Long N,et al.Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer.J Clin Oncol,2018,36(28):2872-2878.
[43] McClure T,Cui W,AsadiK,et al.Case of nivolumab-induced sclerosing cholangitis:lessons from long-term follow-up.BMJ Open Gastroenterol,2020,7(1):e000487.
[44] Terziroli Beretta-Piccoli B,Mieli-Vergani G,Vergani D,et al.The challenges of primary biliary cholangitis:what is new and what needs to be done.J Autoimmun,2019,105:102328.
[45] Roma MG,Toledo FD,Boaglio AC,et al.Ursodeoxycholic acid in cholestasis: linking action mechanisms to therapeutic applications.Clin Sci (Lond),2011,121(12):523-544.
[46] Sato K,Hayashi M,Abe K,et al.Pembrolizumab-induced sclerosing cholangitis in a lung adenocarcinoma patient with a remarkable response to chemotherapy: a case report.Clin J Gastroenterol,2020,13(6):1310-1314.
[47] Ziogas DC,Gkoufa A,Cholongitas E,et al.When steroids are not enough in immune-related hepatitis:current clinical challenges discussed on the basis of a case report.J Immunother Cancer,2020,8(2):e001322.
[48] Fa’ak F,Buni M,Falohun A,et al.Selective immune suppression using interleukin-6 receptor inhibitors for management of immune-related adverse events.J Immunother Cancer,2023,11(6):e006814.
[49] Schön V,Stocker D,Jüngst C,et al.Immune-related sclerosing cholangitis and subsequent pyogenic liver abscesses in two patients with melanoma treated by triplet therapy:a case report.J Immunother,2023,46(9):346-350.